Literature DB >> 2300238

T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors.

H P Hartung1, R A Hughes, W A Taylor, K Heininger, K Reiners, K V Toyka.   

Abstract

Guillain-Barré syndrome (GBS), chronic idiopathic demyelinating polyradiculoneuropathy (CIDP), and multiple sclerosis (MS) are disorders with presumed immunopathogenesis. To obtain evidence for T cell activation, we determined serum concentrations of soluble interleukin-2 receptors (sIL-2 R) in 50 patients with GBS, 24 with CIDP, and 54 with MS. Both in GBS and clinically active MS sIL-2 R levels were markedly increased compared with those in patients with other neurologic diseases. Four of 24 CIDP patients had abnormally increased sIL-2 R concentrations. sIL-2 R concentrations decreased with clinical improvement in serial samples taken from GBS patients, but were not otherwise correlated with disease severity. These data establish that T cells are activated in GBS and some patients with CIDP, and corroborate earlier evidence that activated T cells are circulating in the blood of MS patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2300238     DOI: 10.1212/wnl.40.2.215

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

Review 1.  Guillain Barré syndrome.

Authors:  J B Winer
Journal:  Mol Pathol       Date:  2001-12

Review 2.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Potential role of transforming growth factor-beta 1 in terminating the immune response in patients with Guillain-Barré syndrome.

Authors:  E Sindern; K Schweppe; L M Ossege; J P Malin
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

Review 4.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function.

Authors:  A Créange; L Bélec; B Clair; J D Degos; J C Raphaël; R K Gherardi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

6.  Optic neuritis in different strains of mice by a recombinant HSV-1 expressing murine interleukin-2.

Authors:  Mandana Zandian; Raelene Belisle; Kevin R Mott; Steven Nusinowitz; Florence M Hofman; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

7.  Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.

Authors:  C E Shaw; P R Dunbar; H A Macaulay; T J Neale
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

8.  Impact of a Demyelination-Inducing Central Nervous System Virus on Expression of Demyelination Genes in Type 2 Lymphoid Cells.

Authors:  Satoshi Hirose; Mihoko Kato; Kati Tormanen; Pedram Shafiei Jahani; Omid Akbari; Homayon Ghiasi
Journal:  J Virol       Date:  2021-01-28       Impact factor: 5.103

9.  An analysis of peripheral type benzodiazepine receptors on blood mononuclear cells during high dose steroid treatment of multiple sclerosis.

Authors:  P Ferrero; P Rocca; P Benna; C De Leo; E Montalenti; L Ravizza; B Bergamasco
Journal:  Ital J Neurol Sci       Date:  1992-11

10.  Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies.

Authors:  T E Feasby
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.